Roger Franklin is Partner at Hadean Ventures, a Nordic-based life science VC. Since completing his PhD at Cambridge, Roger has gained experience across VC, banking and strategy consulting for almost two decades. He has sat on the board of multiple current and former Hadean portfolio companies, as director or observer, including Emergence Tx (acquired by Eli Lilly in 2023), Cardior (acquired by Novo Nordisk in 2024 for up to c.€1bn), Contineum (US Nasdaq IPO in 2024) and Abliva (acquired by Pharming in 2025).